A detailed history of Parallel Advisors, LLC transactions in Cassava Sciences Inc stock. As of the latest transaction made, Parallel Advisors, LLC holds 244 shares of SAVA stock, worth $617. This represents 0.0% of its overall portfolio holdings.

Number of Shares
244
Previous 244 -0.0%
Holding current value
$617
Previous $3,000 133.33%
% of portfolio
0.0%
Previous 0.0%

Shares

10 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 08, 2024

SELL
$12.35 - $26.11 $123 - $261
-10 Reduced 3.94%
244 $3,000
Q4 2023

Feb 09, 2024

BUY
$12.64 - $30.11 $3,084 - $7,346
244 Added 2440.0%
254 $5,000
Q2 2023

May 20, 2024

SELL
$21.59 - $27.88 $496 - $641
-23 Reduced 69.7%
10 $0
Q2 2023

Aug 04, 2023

SELL
$21.59 - $27.88 $496 - $641
-23 Reduced 69.7%
10 $0
Q1 2023

May 20, 2024

SELL
$23.46 - $36.44 $5,184 - $8,053
-221 Reduced 87.01%
33 $0
Q1 2023

Apr 25, 2023

BUY
$23.46 - $36.44 $539 - $838
23 Added 230.0%
33 $0
Q1 2022

Apr 28, 2022

SELL
$32.6 - $53.05 $65 - $106
-2 Reduced 16.67%
10 $0
Q4 2021

Jan 20, 2022

SELL
$36.77 - $90.91 $294 - $727
-8 Reduced 40.0%
12 $1,000
Q2 2021

Aug 06, 2021

BUY
$32.15 - $89.72 $321 - $897
10 Added 100.0%
20 $2,000
Q1 2021

Apr 23, 2021

BUY
$7.09 - $87.95 $70 - $879
10 New
10 $0

Others Institutions Holding SAVA

About CASSAVA SCIENCES INC


  • Ticker SAVA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 40,097,900
  • Market Cap $101M
  • Description
  • Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's...
More about SAVA
Track This Portfolio

Track Parallel Advisors, LLC Portfolio

Follow Parallel Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Parallel Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Parallel Advisors, LLC with notifications on news.